AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11255520 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐dose ramipril for 90 days
Number of subjects: 352
Study 9449057 — intervention group
Group type: EXPERIMENTAL
Intervention: Various local and nonlocal (distant) complementary healing methods
Number of subjects: 0
Study 9449057 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled protocols
Number of subjects: 0
Study 7949208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole (CGS 16949A)
Number of subjects: 0
Study 7949208 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (CGS 20267)
Number of subjects: 0
Study 3109893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788
Number of subjects: 0
Study 3109893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antagonist)
Number of subjects: 0
Study 29611407 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Pedicle Screw Fixation (Robot-PSF)
Number of subjects: 78
Study 29611407 — intervention group
Group type: COMPARATOR
Intervention: Conventional Freehand Pedicle Screw Fixation (Conv-PSF)
Number of subjects: 78
Study 28801421 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group receiving 10 sessions of EA treatment over 4 weeks
Number of subjects: 45
Study 28801421 — intervention group
Group type: COMPARATOR
Intervention: Sham EA group receiving sham EA at non-acupoints using non-penetrating Streitberger acupuncture needles with mock EA
Number of subjects: 45
Study 28801421 — intervention group
Group type: COMPARATOR
Intervention: Usual care group not receiving EA treatment
Number of subjects: 45
Study 25628424 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 30
Study 24122389 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine (docetaxel: 75 mg/m2 on day 1; capecitabine: 1,650 mg/m2 on days 1–14 every 3 weeks)
Number of subjects: 477
Study 24122389 — intervention group
Group type: COMPARATOR
Intervention: docetaxel alone (75 mg/m2 on day 1 every 3 weeks)
Number of subjects: 477
Study 24122389 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine
Number of subjects: 477
Study 24122389 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-treatment Ki67LI
Number of subjects: 477
Study 21029339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 12000
Study 21029339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 12000
Study 21029339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study 21029339 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 12000
Study 21029339 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 12000
Study 21029339 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 12000
Study 21029339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 12000
Study 18571985 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 1572
Study 18571985 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study 16823593 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy group treated with mitomycin C, 5‐fluorouracil (5‐FU), and HCFU
Number of subjects: 984
Study 16823593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative adjuvant chemotherapy)
Number of subjects: 984
Study 16823593 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy group
Number of subjects: 984
Study 16823593 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 984
Study 16823593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 984
Study 12783913 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/d paroxetine CR
Number of subjects: 165
Study 12783913 — intervention group
Group type: EXPERIMENTAL
Intervention: 25.0 mg/d paroxetine CR
Number of subjects: 165
Study 12783913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 10770448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (100-300 mg/day)
Number of subjects: 248
Study 10770448 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 248
Study 10770448 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg/day)
Number of subjects: 248
Study 10770448 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 248
Study 8814842 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation of the prostate
Number of subjects: 148
Study 8814842 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 148
Study 1299708 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg isoniazid (INH)
Number of subjects: 772
Study 1299708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772
Study 1299708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (INH and placebo)
Number of subjects: 772
Study 31048088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day)
Number of subjects: 0
Study 31048088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29663513 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 300
Study 27376711 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study 27376711 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 0
Study 24951609 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (capecitabine or fluorouracil, plus cisplatin)
Number of subjects: 0
Study 24951609 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0
Study 24951609 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 22021274 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages advocating skin self-examination (SSE)
Number of subjects: 169
Study 22021274 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages advocating skin self-examination (SSE)
Number of subjects: 169
Study 21047164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health care services response to domestic violence
Number of subjects: 0
Study 17593405 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-StabEx (physiotherapy, spine stabilisation exercises)
Number of subjects: 159
Study 17593405 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-Mixed (physiotherapy, mixed techniques)
Number of subjects: 159
Study 17593405 — intervention group
Group type: COMPARATOR
Intervention: Keep active (CONTROL)
Number of subjects: 159
Study 16358878 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex (Groprinosin) 50 mg/kg b.w/day for 10 days in 3 following months
Number of subjects: 30
Study 16358878 — intervention group
Group type: COMPARATOR
Intervention: Garlic (Alliofil)
Number of subjects: 30
Study 12218200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumicing prior to bonding with Right-On
Number of subjects: 60
Study 12218200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumicing prior to bonding with Fuji II LC
Number of subjects: 60
Study 12218200 — intervention group
Group type: COMPARATOR
Intervention: No pumicing prior to bonding with Right-On
Number of subjects: 60
Study 12218200 — intervention group
Group type: COMPARATOR
Intervention: No pumicing prior to bonding with Fuji II LC
Number of subjects: 60
Study 12218200 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of resin-modified glass poly(alkenoate) cement (Fuji II LC)
Number of subjects: 60
Study 9856371 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (25 mmol/day or 1 g/day of calcium as calcium carbonate)
Number of subjects: 60
Study 9856371 — intervention group
Group type: COMPARATOR
Intervention: Control period (no calcium supplementation)
Number of subjects: 60
Study 8557956 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term contact lens wear (30-hour period including overnight)
Number of subjects: 16
Study 8557956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recent contact-lens-wearing experience)
Number of subjects: 16
Study 8557956 — intervention group
Group type: EXPERIMENTAL
Intervention: Neophyte group (8 subjects fitted with lenses)
Number of subjects: 16
Study 8557956 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced group (6 contact lens wearers)
Number of subjects: 16
Study 2212020 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral streptomycin/lidocaine injections (S/L)
Number of subjects: 17
Study 2212020 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 17
Study 38214 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg labetalol
Number of subjects: 0
Study 38214 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg labetalol
Number of subjects: 0
Study 38214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31549255 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) with inhaled corticosteroids (ICS) alone or in combination with a long-acting β2-agonist (ICS/LABA)
Number of subjects: 775900
Study 31237450 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body resistance exercise protocol (EX)
Number of subjects: 19
Study 31237450 — intervention group
Group type: COMPARATOR
Intervention: 20-min rest (CON)
Number of subjects: 19
Study 28558825 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise program in addition to usual care
Number of subjects: 140
Study 28558825 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 26130237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg enteral, twice a day for up to seven days)
Number of subjects: 38
Study 26130237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day for up to seven days)
Number of subjects: 38
Study 24259599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 30
Study 24259599 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 30
Study 21048514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% flunarizine
Number of subjects: 10
Study 21048514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18838149 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel plus artesunate
Number of subjects: 312
Study 18838149 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel plus placebo
Number of subjects: 312
Study 18838149 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus placebo
Number of subjects: 312
Study 18838149 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 312
Study 17913695 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick strategy (ICD implanted without EPS and pre-discharge test)
Number of subjects: 190
Study 17913695 — intervention group
Group type: COMPARATOR
Intervention: Extensive strategy (EPS, extensive DFT-test, and pre-discharge test)
Number of subjects: 190
Study 17913695 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick strategy
Number of subjects: 190
Study 17913695 — intervention group
Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 190
Study 15041084 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone
Number of subjects: 26
Study 15041084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11281339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 31
Study 11281339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (90 mg/day)
Number of subjects: 31
Study 9134507 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized developmental care
Number of subjects: 0
Study 9134507 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of nursery care (Control)
Number of subjects: 0
Study 8201073 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (flooding)
Number of subjects: 72
Study 8201073 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 72
Study 8201073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3295317 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% BCAA intravenous solution
Number of subjects: 40
Study 3295317 — intervention group
Group type: COMPARATOR
Intervention: 23% BCAA intravenous solution
Number of subjects: 40
Study 30929570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RIC and PostC in addition to primary PCI
Number of subjects: 696
Study 30929570 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI (control)
Number of subjects: 696
Study 30929570 — intervention group
Group type: EXPERIMENTAL
Intervention: PostC alone in addition to primary PCI
Number of subjects: 696
Study 28729154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg) every 4 weeks for 7 doses and every 12 weeks thereafter until treatment discontinuation
Number of subjects: 571
Study 28729154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 28729154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 571
Study 25987645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (performed on 20 participants over 4 weeks, 3 times per week, each session lasting half an hour)
Number of subjects: 42
Study 25987645 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (20 patients took 0.5 mg once a day for 2 weeks, then 0.5 mg in the morning and evening for the next 2 weeks)
Number of subjects: 42
Study 23372745 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.36 g/d EPA and DHA
Number of subjects: 54
Study 23372745 — intervention group
Group type: COMPARATOR
Intervention: Butter fat (control)
Number of subjects: 54
Study 21515479 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV) without positive end-expiratory pressure (PEEP) (VT=8 ml/kg, Rf=12/min)
Number of subjects: 30
Study 21515479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV) with maintenance of an identical peak pressure (Ppeak) (Rf=12/min, PEEP=0)
Number of subjects: 30
Study 21515479 — intervention group
Group type: EXPERIMENTAL
Intervention: Small tidal volume ventilation with PEEP (VT=6 ml/kg, Rf=16/min, PEEP=5 cm H(2)O)
Number of subjects: 30
Study 21515479 — intervention group
Group type: COMPARATOR
Intervention: Control group (TLV)
Number of subjects: 30
Study 19637348 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal MTP‐PE
Number of subjects: 91
Study 19637348 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (3-drug chemotherapy without ifosfamide)
Number of subjects: 91
Study 17303322 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake surgery
Number of subjects: 53
Study 17303322 — intervention group
Group type: COMPARATOR
Intervention: Surgery under general anesthesia (GA)
Number of subjects: 53
Study 15185266 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-skills promotion program (six-session school-based program)
Number of subjects: 258
Study 15185266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 258
Study 11570021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (20 mg/d)
Number of subjects: 555
Study 11570021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 9725754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 36
Study 9725754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.026 mg/kg
Number of subjects: 36
Study 9725754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9725754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (both dosages)
Number of subjects: 36
Study 7978471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 40 mg.kg‐1 infused over 60 min after induction of anesthesia and 4 h later
Number of subjects: 66
Study 7978471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DCA)
Number of subjects: 66
Study 2568015 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 2568015 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids in very high doses
Number of subjects: 0
Study 2568015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetic drugs
Number of subjects: 0
Study 2568015 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 2568015 — intervention group
Group type: COMPARATOR
Intervention: Antacids, antacid/alginate, metoclopramide, domperidone
Number of subjects: 0
Study 29391346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 786
Study 29391346 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation (AF)
Number of subjects: 786
Study 28768528 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC + HA group (75 million allogeneic mesenchymal precursor cells suspended in hyaluronan)
Number of subjects: 17
Study 28768528 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC + HA group
Number of subjects: 17
Study 28768528 — intervention group
Group type: COMPARATOR
Intervention: HA group (control)
Number of subjects: 17
Study 26168497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (Group B)
Number of subjects: 23
Study 26168497 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 23
Study 21138861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128
Study 21138861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study 18340390 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) with long-acting diltiazem (240 mg/day)
Number of subjects: 270
Study 18340390 — intervention group
Group type: COMPARATOR
Intervention: Standard office-based management (Control group)
Number of subjects: 270
Study 17154747 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 130
Study 17154747 — intervention group
Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 130
Study 17154747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (IBCT and TBCT)
Number of subjects: 130
Study 12665170 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Educational Videotaped Interventions (IEVI)
Number of subjects: 0
Study 9656540 — intervention group
Group type: COMPARATOR
Intervention: Lactose free formula with higher levels of calcium (FSL)
Number of subjects: 19
Study 9656540 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard starting formula (FI)
Number of subjects: 19
Study 7642086 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated ALL patients
Number of subjects: 36
Study 7642086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow cell nuclei in untreated ALL patients
Number of subjects: 36
Study 7642086 — intervention group
Group type: COMPARATOR
Intervention: Children in remission from ALL
Number of subjects: 36
Study 2753374 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal respite care
Number of subjects: 642
Study 596287 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 gm of alcohol/kg body weight)
Number of subjects: 14
Study 596287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.05 gm/kg)
Number of subjects: 14
Study 31188778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 9 individual sessions (weekly one session)
Number of subjects: 20
Study 31188778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 27837036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production (EHFP) program consisting of home garden, poultry raising, and nutrition education implemented over 2.5 years
Number of subjects: 2106
Study 27837036 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2106
Study 24286408 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV treatment group (NPPV group)
Number of subjects: 95
Study 24286408 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (control group)
Number of subjects: 95
Study 20924751 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16
Study 20924751 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol clamp (blood alcohol concentration = 0.6‰)
Number of subjects: 16
Study 20924751 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA + THC (inhalation of 4, 6 and 6 mg, interval of 1.5 h)
Number of subjects: 16
Study 20924751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19364364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 20
Study 19364364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17567341 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% with 75 microg fentanyl (1.5 ml)
Number of subjects: 112
Study 17567341 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.5% with 1.5 ml saline
Number of subjects: 112
Study 15142216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume evacuation (HVE)
Number of subjects: 6
Study 15142216 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental suction (CDS)
Number of subjects: 6
Study 11359492 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIPN dressing
Number of subjects: 20
Study 9828549 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates born to mothers with pre‐eclamptic toxaemia (PET)
Number of subjects: 90
Study 9828549 — intervention group
Group type: COMPARATOR
Intervention: Neonates born to mothers with normal conditions
Number of subjects: 90
Study 7927233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐galactosyl‐neoglycoalbumin (radiolabeled asialoglycoprotein analog)
Number of subjects: 85